Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 04/02/2018
Entire Document
 
 

 

10.31   License Agreement, dated August 17, 2017, between BioTime, Inc. and AgeX Therapeutics, Inc. (28)
     
10.32   Option to Purchase Shares of AgeX Therapeutics, Inc., dated August 4, 2017, granted by BioTime, Inc. to Alfred D. Kingsley (28)
     
10.33   AgeX Therapeutics, Inc. 2017 Equity Incentive Plan (29)
     
10.34   Form of AgeX Therapeutics, Inc. Stock Option Agreement (29)
     
10.35   Amendment, dated January 8, 2018, to Second Amended and Restated License Agreement, dated June 15, 2017, between Cell Cure Neurosciences, Ltd. and Hadasit Medical Research Services and Development (30)
     
21.1   List of Subsidiaries (30)
     
23.1   Consent of OUM & Co. LLP (30)
     
23.2   Consent of OUM & Co. LLP for Financial Statements of Asterias Biotherapeutics, Inc.(30)
     
23.3   Consent of OUM & Co. LLP for Financial Statements of OncoCyte Corporation.*
     
31   Rule 13a-14(a)/15d-14(a) Certification *
     
32   Section 1350 Certification *
     
99.1   Financial Statements of Asterias Biotherapeutics, Inc. (30)
     
99.2   Financial Statements of OncoCyte Corporation*
     
101   Interactive Data File
     
101.INS   XBRL Instance Document (30)
     
101.SCH   XBRL Taxonomy Extension Schema (30)
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase (30)
     
101.LAB   XBRL Taxonomy Extension Label Linkbase(30)
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase(30)
     
101.DEF   XBRL Taxonomy Extension Definition Document(30)

 

  (1) Incorporated by reference to BioTime’s Current Report on Form 8-K/A, filed with the Securities and Exchange Commission on August 14, 2017
     
  (2) Incorporated by reference to BioTime’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on September 7, 2017
     
  (3) Incorporated by reference to Registration Statement on Form S-1, File Number 33-44549 filed with the Securities and Exchange Commission on December 18, 1991, and Amendment No. 1 and Amendment No. 2 thereto filed with the Securities and Exchange Commission on February 6, 1992 and March 7, 1992, respectively
     
  (4) Incorporated by reference to BioTime’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 3, 2013
     
  (5) Incorporated by reference to BioTime’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 23, 2014
     
  (6) Incorporated by reference to BioTime’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009
     
  (7) Incorporated by reference to BioTime’s Annual Report on Form 10-KSB for the year ended December 31, 2007
     
  (8) Incorporated by reference to BioTime’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 9, 2008
     
  (9) Incorporated by reference to BioTime’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2008
     
  (10) Incorporated by reference to BioTime’s Annual Report on Form 10-K for the year ended December 31, 2008

 

 5 

© Copyright BioTime, Inc.